Adaptimmune Therapeutics's EBITDA per Share for the
three
months ended in Dec. 2023 was $-0.21.
Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.60.
During the past 3 years, the average EBITDA per Share Growth Rate was 10.30% per year.
During the past 5 years, the average EBITDA per Share Growth Rate was 4.40% per year.
During the past 10 years, the average EBITDA per Share Growth Rate was -34.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.
The historical rank and industry rank for Adaptimmune Therapeutics's EBITDA per Share or its related term are showing as below:
ADAP'
s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -254.7 Med: -6.6 Max: 10.3
Current: 10.3
During the past 12 years, the highest 3-Year average EBITDA per Share Growth Rate of Adaptimmune Therapeutics was 10.30% per year. The lowest was -254.70% per year. And the median was -6.60% per year.
ADAP's 3-Year EBITDA Growth Rate is ranked better than 56% of 1291
companies
in the Biotechnology industry
Industry Median: 6.1
vs ADAP: 10.30
Adaptimmune Therapeutics's EBITDA for the
three
months ended in Dec. 2023 was $-46.99 Mil.
During the past 3 years, the average EBITDA Growth Rate was -0.60% per year.
During the past 5 years, the average EBITDA Growth Rate was -10.30% per year.
During the past 10 years, the average EBITDA Growth Rate was -32.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 12 years, the highest 3-Year average EBITDA Growth Rate of Adaptimmune Therapeutics was -0.60% per year. The lowest was -95.60% per year. And the median was -25.80% per year.
Adaptimmune Therapeutics EBITDA per Share Historical Data
The historical data trend for Adaptimmune Therapeutics's EBITDA per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Adaptimmune Therapeutics Annual Data
Trend
Jun14
Jun15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EBITDA per Share
-1.26
-0.88
-1.00
-0.97
-0.64
Adaptimmune Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EBITDA per Share
-0.14
0.03
-0.23
-0.19
-0.21
Adaptimmune Therapeutics EBITDA per Share Calculation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Adaptimmune Therapeutics's EBITDA per Share for the fiscal year that ended in Dec. 2023 is calculated as
EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.60
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptimmune Therapeutics (NAS:ADAP) EBITDA per Share Explanation
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to:
Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners
EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Be Aware
Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.
Adaptimmune Therapeutics EBITDA per Share Related Terms
Thank you for viewing the detailed overview of Adaptimmune Therapeutics's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADAP has been successfully added to your 